Clover Health Investments, Corp. (CLOV) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$2.82
Price Target
$3.33
Target Range
$1.80 — $6.00
Analyst Rating
Hold
Forward P/E65.9x
Trailing P/E-16.6x
Forward PEG—
Implied Growth+139.3%
Median Target$2.75
Analyst Spread126.1%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$2
-36.2%
Consensus
$3
+18.1%
Bull Case
$6
+112.8%
CLOV Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Clover Health Investments, Corp. (CLOV) has a Wall Street consensus price target of $3.33, based on estimates from 9 covering analysts. With the stock currently trading at $2.82, this represents a potential upside of +18.1%. The company has a market capitalization of $1.44B.
Analyst price targets range from a low of $1.80 to a high of $6.00, representing a 126% spread in expectations. The median target of $2.75 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 1 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 3 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, CLOV trades at a trailing P/E of -16.6x and forward P/E of 65.9x. Analysts expect EPS to grow +139.3% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+13.9%
Avg Forward P/E37.9x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 HUMHumana Inc. | $29.7B | $247.14 | $246.00 | -0.5% | Hold | 27.7x | 44 |
 CVSCVS Health Corporation | $111.4B | $87.31 | $95.20 | +9.0% | Buy | 12.2x | 41 |
 ELVElevance Health Inc. | $81.0B | $372.90 | $382.38 | +2.5% | Buy | 13.9x | 37 |
 CNCCentene Corporation | $27.1B | $54.95 | $51.00 | -7.2% | Buy | 16.3x | 43 |
 MOHMolina Healthcare, Inc. | $10.0B | $191.81 | $166.09 | -13.4% | Buy | 37.2x | 38 |
 ALHCAlignment Healthcare, Inc. | $3.7B | $18.25 | $24.83 | +36.1% | Buy | 140.9x | 16 |
 OSCROscar Health, Inc. | $5.4B | $20.87 | $16.75 | -19.7% | Hold | 34.7x | 11 |
 BHVNBiohaven Ltd. | $1.0B | $9.73 | $21.29 | +118.7% | Buy | — | 25 |
 UNHUnitedHealth Group Incorporated | $335.6B | $369.74 | $385.43 | +4.2% | Buy | 20.2x | 52 |
 TDOCTeladoc Health, Inc. | $1.3B | $6.96 | $7.58 | +8.9% | Hold | — | 42 |
Upside Potential Comparison
BHVNALHCCVSTDOCUNHELVHUMCNCSee CLOV's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CLOV Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CLOV vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCLOV — Frequently Asked Questions
Quick answers to the most common questions about buying CLOV stock.
What is the CLOV stock price target for 2026?
Clover Health Investments, Corp. (CLOV) has a consensus 12-month price target of $3.33, implying 18.1% upside from $2.82. The 9 analysts covering CLOV see moderate appreciation potential.
Is CLOV a buy, sell, or hold?
CLOV has a consensus rating of "Hold" based on 9 Wall Street analysts. The rating breakdown is leaning bearish, with 3 Sell/Strong Sell ratings. The consensus 12-month price target of $3.33 implies 18.1% upside from current levels.
Is CLOV stock overvalued or undervalued?
At a forward P/E of 65.8879x, CLOV trades at a premium valuation. The consensus price target of $3.33 (18.1% upside) suggests analysts still see growth justifying the multiple.
How high can CLOV stock go?
The most bullish Wall Street analyst has a price target of $6 for CLOV, while the most conservative target is $1.8. The consensus of $3.33 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover CLOV stock?
CLOV is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 5 recommend Hold, and 3 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the CLOV stock forecast?
The 12-month CLOV stock forecast based on 9 Wall Street analysts shows a consensus price target of $3.33, with estimates ranging from $1.8 (bear case) to $6 (bull case). The median consensus rating is "Hold".
What is CLOV's forward P/E ratio?
CLOV trades at a forward P/E ratio of 65.9x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy CLOV stock?
Wall Street analysts are optimistic on CLOV, with a "Hold" consensus rating and $3.33 price target (18.1% upside). 1 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do CLOV price targets vary so much?
CLOV analyst price targets range from $1.8 to $6, a 126% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $3.33 consensus represents the middle ground.